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Background: Post-surgery therapies are given to early-stage breast cancer patients due to the possibility of residual
micrometastasis, and optimized by clincopathological parameters such as tumor stage, and hormone receptor/
lymph node status. However, current efficacy of post-surgery therapies is unsatisfactory, and may be varied
according to unidentified patient genetic factors. Increases of breast cancer occurrence and recurrence have been
associated with dyslipidemia, which can attribute to other known risk factors of breast cancer including obesity,
diabetes and metabolic syndrome. Thus we reasoned that dyslipidemia-associated nucleotide polymorphisms
(SNPs) on the APOA1/C3/A5 gene cluster may predict breast cancer risk and tumor progression.
Methods: We analyzed the distribution of 5 selected APOA1/C3/A5 SNPs in recruited Taiwanese breast cancer
patients (n=223) and healthy controls (n=162). The association of SNP (APOA1 rs670) showing correlation with
breast cancer with baseline and follow-up parameters was further examined.
Results: APOA1 rs670 A allele carriage was higher in breast cancer patients than controls (59.64% vs. 48.77%,
p=0.038). The rs670 A allele carrying patients showed less favorable baseline phenotype with positive lymph nodes
(G/A: OR=3.32, 95% CI=1.77-6.20, p<0.001; A/A: OR=2.58, 95% CI=1.05-6.32, p=0.039) and negative hormone receptor
expression (A/A: OR=4.85, 95%CI=1.83-12.83, p=0.001) in comparison to G/G carriers. Moreover, rs670 A/A carrying
patients had higher risks in both tumor recurrence (HR=3.12, 95% CI=1.29-7.56, p=0.012) and mortality (HR=4.36,
95% CI=1.52-12.47, p=0.006) than patients with no A alleles after adjustments for associated baseline parameters.
Furthermore, the prognostic effect of rs670 A/A carriage was most evident in lymph node-negative patients,
conferring to the highest risks of recurrence (HR=4.98, 95% CI=1.40-17.70, p=0.013) and mortality (HR=9.87, 95%
CI=1.60-60.81, p=0.014) than patients with no A alleles.
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Conclusions: APOA1 rs670 A/A carriage showed poor post-surgery prognosis in Taiwanese lymph node-negative
breast cancer patients, whose prognosis were considered better and adjuvant treatment might be less stringent
according to currently available assessment protocols. Our findings suggest that APOA1 rs670 indicate a
post-surgery risk of breast cancer disease progression, and that carriers of this SNP may benefit from more
advanced disease monitoring and therapy regimens than the current regular standards. Furthermore, control of
lipid homeostasis might protect APOA1 rs670 minor allele carriers from breast cancer occurrence and progression.
Keywords: APOA1/C3/A5, SNP, APOA1 rs670, Lymph node micrometastasis, Post-surgery, PrognosisBackground
Breast cancer is currently the leading cause of cancer
deaths in females worldwide, and also the second most
common cancer after lung cancer [1]. The current thera-
peutic regimens for operable early-stage breast cancers
include endocrine therapy, chemotherapy and radiother-
apy. The assessment tools for post-surgery planning are
currently based on clinicopathological evaluations, but
are unsatisfactory requiring finer adjustments [2]. The
risk factors for breast cancer poor prognosis include
positive sentinel lymph node metastasis, hormone recep-
tor negativity, larger tumor size, younger age, and meno-
pausal status [2]. In contrast to the Western population,
the breast cancer incidence peaks at a younger age in
Oriental Asians, which include Taiwanese [3,4]. Never-
theless, the westernized dietary pattern and lifestyle in
Taiwan in the last two decades has increased the inci-
dences of metabolic disorders, including dyslipidemia, as
well as breast cancer in Taiwanese females [4].
Both cohort and case–control epidemiological obser-
vations have demonstrated the association of metabolic
syndrome, obesity and diabetes with increased breast
cancer risk [5,6]. Dyslipidemia often occur in parallel to
obesity and diabetes, and is a component of metabolic
syndrome [7]. Dyslipidemia in the forms of hypertriglyc-
eridemia, hypercholesterolemia, and low high density
lipoprotein-cholesterol (HDL-C) have been observed in
breast cancer patients of several ethnic groups [8-11].
Moreover, in large cohort studies dyslipidemia is associ-
ated with increased breast cancer risk and poor progno-
sis [12-14]. The intake of lipid-lowering drugs or agents
in women was associated with reduced breast cancer oc-
currence and recurrence risk [15-17]. Consistently,
mammary tumor growth and metastasis was accelerated
in a hyperlipidemic murine model [18].
The APOA1/C3/A5 gene cluster transcribes for
apolipoproteins (apo) A1, C3 and A5, which regulate
HDL-formation and lipoprotein lipase activity [19]. Single-
nucleotide polymorphisms (SNPs) on the APOA1/C3/A5
gene cluster are associated with metabolic syndrome,
dyslipidemia and diabetes [19]. APOA1 rs670 is associated
with altered HDL-C levels, and increased risks of coronary
artery disease and metabolic syndrome [20-25]. APOC3rs2854116 and rs2854117 are correlated to insulin resist-
ance and non-alcoholic liver steatosis [26]. APOA5
rs662799 and rs2075291 carriers are known to have in-
creased plasma triglyceride [27,28], and our recent study
showed correlation of APOA5 rs662799 with central obes-
ity in males [29]. Though the effects of these SNPs on
APOA1/C3/A5 on metabolic disorders have been widely
studied and reviewed, their contributions to breast cancer
have not been determined in detail.
In this study, we first tested the correlation of 5 se-
lected well-known SNPs on the APOA1/C3/A5 gene
cluster with breast cancer in a case–control manner.
Furthermore, we analyzed the effect of the SNPs associ-
ated with greatest breast cancer risk on patient baseline
tumor characteristics, and their post-surgery outcome
after a mean follow-up period of 10.4 years. Finally, we
specifically examined the prognostic value of APOA1
rs670 in lymph node-negative breast cancer patients.
Methods
Patient recruitment
Taiwanese female breast cancer patients (n=223, 48.4±
10.2 years, ranged 29–75 years) received surgical inter-
vention plus axillary/sentinel lymph node dissection dur-
ing 1999–2005 at National Cheng Kung University
Hospital (NCKUH) and Tainan Hospital, and were
followed-up to November 2012. Healthy female controls
(n=162, 43.0 ± 8.8 years, ranged 19.0–69.0 years.) were
also recruited. This is a continuation study of Hsiao
et al., 2004 [30]. Bodyweight (kg) and body height (m)
were measured at the time of mastectomy, and used for
calculating body mass index (BMI, kg m-2). The diagno-
sis was confirmed by histological examinations of mam-
mary and node specimens. Estrogen receptor (ER) and
progesteron receptor (PR) expressions in primary breast
tumor were determined as described previously [31]. In-
dividuals with at least one first-degree or second-degree
female relatives affected by breast cancer were consid-
ered to have a family history. This information was
obtained by interview with patients and their family
members. The recruited patients received tamoxifen
(TAM) (n=92), TAM and chemotherapy (n=56), TAM
and radiotherapy (n=10), and triple-therapy (n=55). This




Age (years) 48.4±10.2 (29–75)
BMIa (kg m-2) 23.36±3.79 (15.06-38.05)
Tumor type
Infiltrating ductal carcinoma 193 (86.55%)
















Stages 0-2 154 (69.06%)
Stages 3-4 30 (13.45%)
Unknown 39 (17.49%)
ER/PR status









TAM only 92 (41.26%)
TAM and chemotherapy 56 (25.11%)
TAM and radiotherapy 10 (4.48%)






Hsu et al. BMC Cancer 2013, 13:330 Page 3 of 11
http://www.biomedcentral.com/1471-2407/13/330study received approval from the local institutional re-
view board (NCKUH IRB) and signed informed consent
was obtained from the patients.
Genomic DNA extraction, SNP genotyping and
linkage analysis
Genomic DNA was extracted from white blood cells
using the Puregene DNA Isolation Kit (Gentra Systems,
Minneapolis, MN, USA). According to criteria described
in Hsu et al. [29], we selected five SNPs on the APOA1/
C3/A4/A5 gene cluster that follows: APOA1 rs670,
APOC3 rs2854116, APOC3 rs2854117, APOA5 rs662799
and APOA5 rs2075291. The SNP genotypes were deter-
mined using commercial real-time PCR primer and
probes from Applied Biosystems (ABI, Foster City, CA,
USA) (APOA5 rs662799 and APOA5 rs2075291) and
TIB MOBIOL (Berlin, Germany) (APOA1 rs670, APOC3
rs2854116 and APOC3 rs2854117). Fluorescence data
from real-time PCRs were collected by a Step-One-Plus
Sequence Detection System (ABI) or LightCycler 480
(Roche, St. Louis, MO, USA). Haploview [32] was used
for the analysis of SNP linkage disequilibrium, and
Hardy-Weinberg equilibrium, and haplotype analysis.
SNP linkage disequilibrium test results with logarithm of
odds (LOD) socores ≥2 and pair-wise D’>0.80 were con-
sidered as significant linkage.
Statistical analysis
The association of SNP with breast cancer risk, baseline
clinical parameters and post-surgery progression was an-
alyzed by Chi-squared test. The odds ratio for unfavor-
able baseline characteristics and events in post-surgery
progression was analyzed by binary or multi-nominal
logistic analysis. The differences in BMI, age, and mean
years in survival were analyzed by one-way ANOVA.
The survival curves of APOA1 rs670 genotype carriers
were plotted by Kaplan-Meier analysis. The hazard ratio
for overall and recurrence-free survival was calculated by
Cox proportional-hazards regression analysis. Possible
confounders including unfavorable baseline characteris-
tics, age and BMI were adjusted for in regression analysis.
Statistical analysis was performed using SPSS 13 (SPSS
Inc., Chicago, DE, USA). In all cases, p-values ≤0.05
were considered statistically significant.
Results
Demographic characteristics of recruited breast
cancer patients
The baseline characteristics of the recruited breast can-
cer patients are shown in Table 1. The mean BMI of
breast cancer patients at baseline was 23.36±3.79 kg m-2.
The major tumor type of recruited patients was infiltrat-
ing ductal carcinoma (86.55%), and the tumor occur-
rence side was evenly distributed (right breast: 44.84%,








NOTE: Values shown are mean±s.d., or number of patients (% of n).
aData from 185 patients. Bold type indicates p<0.050.
Abbreviations: BMI Body mass index, ER estrogen receptor, PR progesterone
receptor, TAM tamoxifen.
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tients were mainly of early-stage breast cancer, as
71.30% of patients had tumors <5 cm, 69.06% were of
tumor stages 0–2, and 64.57% of patients had single or
double positive for ER and PR. Additionally, 53.81% of
patients had detectable lymph node involvement, and
only 5.83% had a family history of breast cancer. The
follow-up period of the breast cancer patients ranged
from 0.14 to 24.52 years (median: 9.93 years), mounting
to 2261.68 person-years in total. About three-forth of
patients (73.99%) remained progression-free of recur-
rence or death. The mean years for recurrence-free and
overall survival were 9.26±5.31 and 10.14±5.11, respect-
ively (Table 1).
ApoA1 rs670 was associated with increased breast
cancer risk
The distributions of the tested SNPs (APOA1 rs670,
APOC3 rs2854116, APOC3 rs2854117, APOA5 rs662799
and APOA5 rs2075291) fitted the Hardy-Weinberg equi-
librium in both breast cancer patients and healthy con-
trols (Additional file 1). Different linkage patterns of the
tested SNPs were observed between breast cancer pa-
tients (Additional file 2). Significant linkage (LOD≥ 2,
D’> 0.80) was observed among APOA1 rs670, APOC3
rs2854116 and APOC3 rs2854117 (D’=0.84-0.88), and
between APOA5 rs662799 and APOA5 rs2075291 in
healthy controls (D’=0.86). In contrast, the linkage
among APOA1 rs670, APOC3 rs2854116 and APOC3
rs2854117 was lost in breast cancer patients, while sig-
nificant linkage was only observed between the two
APOA5 SNPs (D’=1.00).
The frequency of APOA1 rs670 A allele (G/A + A/A)
carriers in breast cancer patients was significantly higher
than that in healthy controls (59.64% vs. 48.77%, p=0.038,
Additional file 3). On the other hand, the genotype and al-
lele frequencies of all other SNPs were comparable be-
tween breast cancer patients and healthy controls. The
post-surgery therapies received by the different APOA1
rs670 genotype carriers were comparable (p=0.151).
Therefore we tested the contribution of APOA1 rs670 tobreast cancer in recruited patients cross-sectionally at
baseline and longitudinally at follow-up.
APOA1 rs670 was associated with sentinel lymph
node-positivity and tumor ER/PR negativity at baseline
Upon analysis of APOA1 rs670 against breast tumor
clinical parameters, we found the mean age and BMI of
different APOA1 rs670 genotype carriers were compar-
able at baseline (Table 2). In contrast, APOA1 rs670 was
associated with nodal involvement as well as tumor hor-
mone receptor expression (Table 2 and 3). Baseline
lymph node positivity was more frequent in patients car-
rying APOA1 rs670 G/A or A/A genotypes than in those
carrying G/G genotype (G/A: 51.89%, A/A: 48.15%, G/G:
24.44%, p=0.002) (Table 2). Moreover, APOA1 rs670 G/
A or A/A carriage also significantly increased the fre-
quency of having tumors double negative for ER/PR ex-
pression than G/G carriage in patients (G/A: 24.53%, A/
A: 48.15%, G/G: 14.44%, p=0.006) (Table 2). In contrast,
APOA1 rs670 was not associated with tumor occurrence
side, type, size, and stage or a family history (Table 2).
The odds of being lymph node-positive in APOA1 rs670
G/A carrying patients (OR=3.32, 95% CI=1.77-6.20, p<
0.001) and APOA1 rs670 A/A carriers (OR=2.58, 95%
CI=1.05-6.32, p=0.039) was higher than G/G carriers
(Table 3). On the other hand, APOA1 rs670 A/A carriers
have significantly higher odds in having ER/PR double-
negative tumors than their G/G counterparts (OR=4.85,
95% CI=1.83-12.83, p=0.001) (Table 3).
APOA1 rs670 A allele carriage was associated with poor
post-surgery outcomes
Higher proportions of APOA1 rs670 G/A and A/A carry-
ing breast cancer patients developed recurrence or death
than G/G carriers (Table 4). The higher incidences of re-
currence in APOA1 rs670 G/A and A/A carriers translate
higher risks to 2.07-fold (95% CI=1.03-4.14, p=0.041) and
3.44-fold (95% CI=1.33-8.86, p=0.011) risk as compared
with G/G carriers, respectively (Table 5). However, the in-
crease in risk of recurrence in APOA1 rs670 G/A carriers
may be confounded by their increased odds in worse base-
line phenotype. After adjustment for lymph node status,
the statistical significance remained in A/A carriers
(OR=2.83, 95% CI, 1.05-7.61, p=0.040), while that in G/A
carriers were diminished (p=0.238) (Table 5). The risk of
death was significantly increased in APOA1 rs670 A/A
carriers (OR=6.03, 95% CI=2.08-17.51, p<0.001) and this
persisted after adjustments for baseline confounders of
lymph node (p=0.007) and ER/PR (p=0.010) status, while
no significant risk was observed in G/A carriers with or
without adjustments (Table 5). The mean years in
recurrence-free survival and overall survival of APOA1
rs670 A/A carriers were significantly shorter than that of
G/A and G/G counterparts (all p<0.001) (Table 4). Despite
Table 2 APOA1 rs670 A allele carriage was associated with lymph node and hormone receptor status at baseline
G/G (n=90) G/A (n=106) A/A (n=27) P valuea
Age 46.61±10.14 (29.25-74.55) 49.98±10.24 (29.87-74.57) 47.83±9.81 (29.25-67.91) 0.067
BMIb 23.47±4.14 (15.06-34.48) 23.03±4.16 (2.25-38.05) 23.77±3.83 (18.18-32.05) 0.654
Tumor type
Infiltrating ductal carcinoma 73 (81.11%) 97 (91.51%) 23 (85.19%)
0.332
Ductal carcinoma in situ 10 (11.11%) 5 (4.72%) 2 (7.41%)
Others 5 (5.56%) 4 (3.77%) 2 (7.41%)
Unknown 2 (2.22%) 0 (0.00%) 0 (0.00%)
Side
Right 35 (38.89%) 52 (49.06%) 13 (48.15%)
0.704Left 51 (56.67%) 50 (47.17%) 13 (48.15%)
Bilateral 4 (4.44%) 4 (3.77%) 1 (3.70%)
Tumor size
<5cm 64 (71.11%) 76 (71.70%) 19 (70.37%)
0.227≥5cm 6 (6.67%) 16 (15.09%) 4 (14.81%)
Unknown 20 (22.22%) 14 (13.21%) 4 (14.81%)
Lymph node involvement
Positive 22 (24.44%) 55 (51.89%) 13 (48.15%)
0.002Negative 61 (67.78%) 46 (43.40%) 14 (51.85%)
Unknown 7 (7.78%) 5 (4.72%) 0 (0.00%)
TMN staging
Stages 0-2 63 (70.00%) 71 (66.98%) 20 (74.07%)
0.194Stages >2 7 (7.78%) 19 (17.92%) 4 (14.81%)
Unknown 20 (22.22%) 16 (15.09%) 3 (11.11%)
ER/PR status
Single or double positive 63 (70.00%) 68 (64.15%)) 13 (48.15%)
0.006Negative 13 (14.44%) 26 (24.53%) 13 (48.15%)
Unknown 14 (15.56%) 12 (11.32%) 1 (3.70%)
Family history
Positive 4 (4.44%) 3 (2.83%) (0.00%)
0.823Negative 81 (90.00%) 97 (91.51%) 25 (92.59%)
Unknown 5 (5.56%) 6 (5.66%) 2 (7.41%)
NOTE: Data shown represent number of patients (% of n) or mean±s.d.. Bold type indicates p<0.050.
a, results of Chi-squared analysis or ANOVA test, depending on the type of parameter analyzed.
b, results from 185 patients.
Abbreviations: ER estrogen receptor, PR progesterone receptor.
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rs670 G/A breast cancer carriers had mean survival years
comparable to their G/G counterparts.APOA1 rs670 A/A carriers had the worst outcome in
lymph node-negative patients
To compare APOA1 rs670 A/A carriage with the other
known risk factors in post-surgery prognosis, we per-
formed Cox regression analysis including ER/PR status,
lymph node involvement, age, BMI and post-surgery adju-
vant in adjusted models. Of specific importance, lymphnode-positivity, ER/PR-negativity, combined therapy, and
APOA1 rs670 A/A carriage showed increased recurrence
and mortality risk in unadjusted models (Table 6). The in-
creased risk of recurrence and mortality observed in
APOA1 rs670 A/A carriers remained significant after ad-
justments for lymph node involvement, ER/PR status, age,
BMI, or post-surgery adjuvant (Additional file 4). When
testing the prognostic effects of lymph node, ER/PR, post-
surgery adjuvant and APOA1 rs670 A/A carrying status in
an adjusted model, the significance of lymph node and
APOA1 rs670 A/A was stronger than of ER/PR and post-
surgery adjuvant (Table 6). Lymph node positivity showed
Table 3 APOA1 rs670 A allele carrying patients had increased odds of lymph node involvement and hormone receptor
expression negativity at baseline
Multinominal logistic regression (using APOA1 rs670 G/G as reference)
APOA1 rs670 G/A APOA1 rs670 A/A
OR 95% Cl P value OR 95% Cl P value
Tumor type (using infiltrating ductal carcinoma as reference)
Ductal carcinoma in situ 0.38 0.12-1.15 0.086 0.64 0.13-3.11 0.575
Others 0.6 0.16-2.32 0.461 1.27 0.23-6.99 0.784
Unknown 0 0-0 N/A 0 0-0 N/A
Side (using right as reference)
Left 0.66 0.37-1.18 0.160 0.69 0.28-1.66 0.402
Bilateral 0.67 0.16-2.87 0.593 0.67 0.07-6.59 0.734
Tumor size (using <5cm as reference)
≥5cm 2.25 0.83-6.08 0.111 2.25 0.57-8.79 0.245
Unknown 0.59 0.28-1.26 0.173 0.67 0.21-2.21 0.515
Lymph node involvement (using positive as reference)
Negative 3.32 1.77-6.20 <0.001 2.58 1.05-6.32 0.039
Unknown 0.95 0.28-3.18 0.930 0 0-0 N/A
TMN staging (using stages 0–2 as reference)
Stages >2 2.41 0.95-6.11 0.064 1.8 0.48-6.79 0.385
Unknown 0.71 0.34-1.49 0.364 0.47 0.13-1.76 0.263
ER/PR status (using positive as reference)
Negative 1.85 0.88-3.92 0.106 4.85 1.83-12.83 0.001
Unknown 0.79 0.34-1.85 0.592 0.35 0.04-2.87 0.326
Family history (using negative as reference)
Positive 0.63 0.14-2.88 0.548 0 0-0 N/A
Unknown 1 0.30-3.40 0.997 1.3 0.24-7.09 0.765
NOTE: Bold type indicates p<0.050.
Abbreviations: CI confidence interval, ER estrogen receptor, PR progesterone receptor, OR odds ratio.
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p= 0.002) and mortality (HR= 5.35, 95% CI=2.25-12.68,
p< 0.001), while APOA1 rs670 A/A carriage in recurrence
(HR=3.12, 95% CI=1.29-7.56, p=0.012) and mortality
(HR=4.36, 95% CI=1.52-12.47, p= 0.006). In contrast, ER/
PR status was associated with mortality but no longer with
recurrence in the adjusted model, while post-surgery adju-
vant shows a reversed pattern (Table 6).Table 4 APOA1 rs670 A allele carriage was associated with po
G/G (n=90) G/A
Recurrence 15 (16.67%) 30
Mortality 8 (8.89%) 15
Mean survival years
Recurrence-free 9.63±4.97 (0.16-21.38) 10.03±5.4
Overall 10.30±4.67 (0.16-21.38) 10.98±5.3
NOTE: Data shown represent number of patients (% of n) or mean±s.d.. Bold type i
a, results of Chi-squared analysis or ANOVA test, depending on the type of paramet
Abbreviations: ER estrogen receptor, PR progesterone receptor.Therefore, to specifically rule out confounding from
baseline lymph node involvement in predicting progno-
sis, we tested the prognostic effect of APOA1 rs670 A/A
carriage in baseline lymph node status-stratified patient
groups. The prognostic effect of APOA1 rs670 A/A car-
riage was only observed in the lymph node-negative pa-
tients (n=121, Table 7 and Figure 1) with higher hazard
risks than non-stratified group (n=223, Table 4 andor post-surgery outcomes
(n=106) A/A (n=27) P valuea
(28.30%) 11 (40.74%) 0.021
(14.15%) 10 (37.04%) 0.002
5 (0.04-24.52) 5.36±4.11 (0.18-17.21) <0.001
2 (0.14-24.52) 6.33±4.00 (0.55-17.21) <0.001
ndicates p<0.050.
er analyzed.
Table 5 APOA1 rs670 A allele carrying patients had increased odds of post-surgery disease progression
rs670 Unadjusted Lymph node-adjusteda ER/PR-adjustedb
OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value
Recurrence G/G 1.00 - 1.00 - 1.00 -
G/A 2.07 (1.03-4.14) 0.041 1.57 (0.74-3.33) 0.238 2.49 (1.14-5.44) 0.022
A/A 3.44 (1.33-8.86) 0.011 2.83 (1.05-7.61) 0.040 3.08 (1.08-8.78) 0.035
Mortality G/G 1.00 - 1.00 - 1.00 -
G/A 1.82 (0.74-4.48) 0.191 2.25 (0.83-6.11) 0.112 1.05 (0.4-2.76) 0.925
A/A 6.03 (2.08-17.51) 0.001 5.14 (1.56-16.97) 0.007 4.45 (1.4-14.15) 0.010
NOTE: Data shown represent number of patients (% of n) or mean±s.d.. Bold type indicates p<0.050.
a, adjusted for lymph node status, n=211.
b, adjusted for ER/PR status, n=196.
Abbreviations: CI confidence interval, ER estrogen receptor, PR progesterone receptor, OR odds ratio.
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APOA1 rs670 A/A carriage did not reach statistical sig-
nificance in node-positive patients (n=90, Table 7 and
Additional file 5 lower panels). The risk of recurrence
associated with APOA1 rs670 A/A carriage was higher
as compared with G/G (HR=4.98, 95% CI=1.40-17.70,
p=0.013) in lymph node-negative breast cancer patients.
The risk of mortality in lymph node-negative APOA1
rs670 A/A carrying breast cancer patients was also
higher than APOA1 rs670 G/G counterparts (HR=9.87,
95% CI=1.60-60.81, p=0.014). The contributions from
ER/PR status, age, BMI, or post-surgery adjuvant inTable 6 APOA1 rs670 A/A carriage predicts poor post-surgery




Lymph node positivitya 2.86 (1.65-4.96)
ER/PR negativityb 1.90 (1.08-3.37)
Age 1.01 (0.98-1.04)
BMIc 1.00 (0.93-1.08)
Combined therapyd 2.64 (1.46-4.78)
APOA1 rs670 A/Ae 4.02 (2.22-9.96)
Mortality
Lymph node positivitya 6.01 (2.62-13.80)
ER/PR negativityb 2.30 (1.13-4.70)
Age 1.03 (0.99-1.06)
BMIc 1.00 (0.91-1.10)
Combined therapyd 3.45 (1.50-7.98)
APOA1 rs670 A/Ae 6.30 (2.47-16.08)
NOTE: P values were results of Cox proportional hazard regression analysis. Bold typ
a, compared with negative lymph node involvement, n=211.
b, compared with ER/PR positive, n=196.
c, n=185.
d, compared with TAM only.
e, compared with APOA1 rs670 G/G.
Abbreviations: BMI Body mass index, ER estrogen receptor, HR Hazard ratio, PR progpredicting outcome remained insignificant in lymph
node-status stratified groups (Table 7).
Discussion
Dyslipidemia is a known complication of TAM-treatment
in breast cancer patients, and increases risk of coronary-
artery diseases in patients [33]. Of equal importance,
dyslipidemia has been observed in breast cancer patients
prior to treatment, and this correlation is supported by
epidemiological studies [8-11]. Concomitantly, usage of
lipid-lowering drugs such as statin and niacin has been
shown to associate with decreased breast cancer recurrencesurvival in breast cancer after adjustments for lymph
Adjusted (n=186)
P value HR (95% CI) P value
<0.001 2.20 (1.18-4.10) 0.013
0.027 1.53 (0.85-2.77) 0.156
0.479 - -
1.000 - -
0.001 2.03 (1.01-4.08) 0.046
0.001 3.02 (1.25-7.29) 0.014
<0.001 2.09 (1.01-4.29) 0.046
0.022 4.54 (1.88-10.94) 0.001
0.127 - -
0.942 - -
0.004 2.11 (0.84-5.31) 0.114
<0.001 4.47 (1.56-12.79) 0.005
e indicates p<0.050.
esterone receptor.
Table 7 APOA1 rs670 A/A carriers has the worst post-surgery outcomes in lymph node-negative patients
Cox proportional hazard regression
Lymph node negative (n=121) Lymph node positive (n=90)
HR 95% CI P value HR 95% CI P value
Recurrence
ER/PR negativitya 2.06 0.80-5.31 0.136 0.62 0.30-0.62 0.202
Age 1.01 0.96-1.05 0.788 1.01 0.98-1.01 0.582
BMI 0.95 0.84-1.08 0.450 1.02 0.92-1.02 0.703
Combined therapyb 2.02 0.83-4.93 0.120 2.12 0.85-5.29 0.107
APOA1 rs670 A/Ac 4.98 1.40-17.70 0.013 2.46 0.86-2.46 0.093
Mortality
ER/PR negativitya 0.24 0.05-1.08 0.064 0.52 0.22-1.18 0.118
Age 1.05 0.98-1.13 0.196 1.02 0.99-1.06 0.262
BMI 0.89 0.71-1.11 0.296 1.03 0.91-1.16 0.648
Combined therapyb 1.83 0.41-8.18 0.430 2.65 0.89-7.88 0.081
APOA1 rs670 A/Ac 9.87 1.60-60.81 0.014 2.86 0.96-8.55 0.060
NOTE: Bold type indicates p<0.050.
a, compared with ER/PR positive.
b, compared with TAM only.
c, compared with APOA1 rs670 G/G.
Abbreviations: BMI Body mass index, ER estrogen receptor, HR Hazard ratio, PR progesterone receptor.
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http://www.biomedcentral.com/1471-2407/13/330and risk [15-17]. SNPs on the APOA1/C3/A5 gene cluster,
which is involved in lipid metabolism, are highly associated
with dyslipidemia, metabolic syndrome, insulin resistance
and responsiveness to relative treatments [19]. However,
the contribution of SNPs on the APOA1/C3/A5 gene
cluster to breast cancer is yet to be defined. In this study,
we tested the effects of dyslipidemia-associated SNPs
on the APOA1/C3/A5 gene cluster: APOA1 rs670, APOC3
rs2854116, APOC3 rs2854117, APOA5 rs662799 and
APOA5 rs2075291 on breast cancer progression in a
Taiwanese patient group with mainly operable early-stage
tumors, and a 10-year follow-up interval. We showed that
only APOA1 rs670 out of the 5 tested SNPs was correlated
to breast cancer, lymph node-positivity, ER/PR double-
negativity at baseline. Furthermore, carriers of both minor
alleles on APOA1 rs670 had shortest survival time and
highest risk in disease progression independent of baseline
characteristics. Moreover, the prognostic value of APOA1
rs670 A/A carriage in the worse post-surgery outcomes
was most evident in lymph node-negative patients.
The rs670 SNP contains a G-to-A substitution at 75bp
upstream of APOA1 transcriptional start site, and is
within a MSPI restriction enzyme recognition [19]. A
cross-sectional study focusing on the association of
APOA1 SNPs with breast cancer and patient phenotype
reported that the -75G/A polymorphism correlated with
breast cancer risk at baseline [34]. However, the slight
discrepancy in associations of -75G/A polymorphism
with ER status observed by us and Hamrita et al. is
likely due to ethnic (Taiwanese vs. Tunisian) and age dif-
ferences (62.7% vs. 38.9% <50years) [34]. Nevertheless,in our longitudinal study we found that APOA1 rs670
predicted worse outcome after adjustment for ER/PR
status, indicating alternative contributions from APOA1
rs670 in cancer progression. ApoA1 is the structural
protein of HDL, and interacts with lecithin cholesterol
acyl transferase, which controls the limiting steps in
HDL maturation and therefore reverse cholesterol trans-
port [19]. The minor allele of APOA1 rs670 has been
correlated to altered HDL-C, diabetes and coronary-
artery disease: lower levels of HDL-C was observed
in Northern Indians [20], and correlated with severe
forms of cardiovascular diseases in Northern Indians,
Caucasians in Spain and Australia [20,24,25]. Moreover,
APOA1 rs670 A/A Spanish carriers had a higher risk of
diabetes than their non-A/A counterparts, though their
HDL-C did not differ significantly [21,22]. As plasma
apoA1 level is regulated by estrogen and thus TAM
treatments, the timing of plasma apoA1 measurement in
breast cancer patients is critical. However, we did not
have access to TAM treatment-naïve plasma of the pa-
tients recruited in this study. Nevertheless, the disease
phenotype associated APOA1 rs670 remains significant
without HDL-C differences, as has been reported in a
number of studies on metabolic/cardiovascular diseases
[21,24,25].
The significance of plasma HDL-C levels in breast
cancer has long been investigated and debated [35]. The
current held view is that higher HDL-C levels, which are
preventive for cardiovascular events, are also protective
for breast cancer. The majority of reports supporting
this view were of case–control design, and found lower
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Figure 1 Kaplan-Meier plots of breast cancer patient
post-surgery survival stratified by APOA1 rs670 genotype. The
recurrence-free (A) and overall disease-specific survival (B) of APOA1
A/A (bold line), G/A (thin line) and G/G (broken line) carrying
lymph-node negative breast cancer patients were compared. The
life tables are shown below the Kaplan-Meier survival plots. Bold
type indicates p<0.050.
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http://www.biomedcentral.com/1471-2407/13/330total or lipid-rich HDL, or higher total cholesterol/HDL-
C ratio in breast cancer patients as compared with non-
cancerous or other cancer controls in various ethnic
groups [8,10,11]. A 17.2-year prospective cohort study
carried out in Norway found that naive females with the
lowest quartile of HDL-C had highest risk of later devel-
oping breast cancer [14]. Moreover, the same Norwegian
group found the breast cancer patients with highest total
cholesterol or lowest plasma HDL-C levels had highest
risk in mortality [13]. The female breast is an active site
of both lipid uptake and lipid secretion during periods
of milk secretion, thus it is readily acceptable that apoA1
is present in human milk [36]. Supportively, apoA1 was
also identified in the breast cancer tissues and ex vivocultured medium. ApoA1 was found in breast tumors,
and its amount was correlated positively with chemo-
therapy resistance in malignant tumors [37]. In contrast,
breast tumors later found responsive to chemotherapy
secreted higher amount of apoA1 than tumors non-
responsive to chemotherapy during short term ex vivo
culture, while non-cancerous tissues secreted highest
amount of apoA1 [38]. Furthermore, a successful reduc-
tion of breast cancer growth in mice by vitamin
D treatment was accompanied by decrease of apoA1
production in tumor tissues [39]. It is at this stage un-
known how much apoA1 in circulation is contributed by
the mammary tissue, but the retention of apoA1 in breast
cancer tissues is in accordance with the observation of
lower plasma HDL/apoA1 in breast cancer patients.
Though the association of plasma lipid profiles and breast
cancer incidence or progression is strongly and continu-
ously suggested, the molecular mechanisms of HDL or
apoA1 in promoting breast cancer risk are still unclear.
Plasma apoA1/lipid-poor HDL bind to ATP-binding
cassette (ABC) lipid transporters during maturation, and
the intracellular cholesterol is exported to load onto
HDL, facilitating reverse cholesterol transport [40]. Sev-
eral members of the ABC family were found in mam-
mary tissues, but only those associated with drug
resistance were increased in breast cancers as compared
with normal tissues [41]. In contrast, ABC transporters
involved in lipid transport, including ABC-A1 and ABC-
A3, were decreased in breast cancer tissues as compared
with healthy mammary glands [42]. In vitro studies
found that over-expression of ABC-G1 in breast cancer
cell line induces cellular cholesterol efflux and apoptosis
[43]. Moreover, ABCA- or ABCG-HDL binding con-
comitantly induces intracellular signaling and suppresses
inflammatory reactions, which is known to be a key fac-
tor in tumorigenesis. Binding of ABCA or ABCG by
apoA1 induces the recruitment of phosphrylated STAT-
3 and JAK2, and thus suppresses the inflammatory path-
ways including TL4-signalling [40]. Furthermore, ABCA
induces Cdc42 and PAK-1 signaling, which in turn are
regulative for breast cancer ER/PR expression in vitro
and in vivo [44,45]. Therefore, the altered HDL/apoA1
levels observed in APOA1 rs670 A carriers may partici-
pate in the tumorigenesis, survival, ER/PR status of
breast cancer cells. In a previous published study, we
found that genetic and intra-tumoral ER polymorphisms
were correlated with breast cancer in Taiwanese females
[30,31]. It would be of interest how APOA1 rs670 and
HDL-C interact with ER polymorphisms both at a sys-
temic and local (mammary tissue) level in these patients.
Clinically, our finding of worst outcome in APOA1 rs670
A/A breast cancer patients as compared to their non-A/A
counterparts provides pivotal implications in personalized
treatment regimen and therapeutic strategies. The median
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http://www.biomedcentral.com/1471-2407/13/330recurrence-free and overall survival years of APOA1 rs670
A/A carrying breast cancer patients were both longer than
the standard chemotherapy duration (~1 year) and the ad-
vised 5-year limit for continuous TAM usage. As the pa-
tients recruited in this study were non-obese and of early
tumor-staging, the administration of adjuvant therapy may
be less intensive. Furthermore, the prognostic value of
APOA1 rs670 was even more evident in the lymph node-
negative patients, who were given less adjuvant therapies
under the current assessment guidelines. Thus APOA1
rs670 A/A carriers may benefit from advanced therapies.
Recent studies demonstrated that administration of apoA1
mimetic peptides reduced the development of cancer in
murine models [46,47]. Furthermore, a large cohort study
on the effect of post-diagnosis statin use in breast cancer
females reported a lowered risk in cancer recurrence [48].
These reports suggest that raising HDL-C or apoA1 may
be preventive or therapeutic for breast cancers, especially
in the APOA1 rs670 A/A carrying patients. On the other
hand, due to the low plasma HDL-C and tumor ER/PR
negativity in the APOA1 rs670 A/A carriers, the usage of
TAM in these breast cancer patients may be controversial
and require further evaluation.Conclusions
In conclusion, we demonstrated the correlation of
dyslipidemia-associated APOA1 rs670 minor allele with
unfavorable baseline characteristics in Taiwanese breast
cancer patients, and the 10-year follow-up revealed pa-
tients carrying both minor alleles had worst survival in
lymph node-negative patients. Though TAM treatment
naïve plasma HDL-C levels of the recruited patients
were unavailable, our data was consistent after appropri-
ate adjustments for possible confounding factors. Our
study provides novel clinical directions for both person-
alized treatment regimen and therapeutic strategies.Additional files
Additional file 1: The distributions of tested SNPs on APOA1/C3/A5
gene cluster in breast cancer patients and healthy controls.
Additional file 2: The linkage disequilibrium pattern of tested
APOA1/C3/A5 SNP gene cluster in the study group. The SNP linkage
pattern in healthy controls (A) and breast cancer patients (B) are shown.
The upper panels show the relative chromosomal localization of the five
SNPs, and the lower panels the test results of linkage disequilibrium by
Haploview. The colour scale shown in the lower panels demonstrates
high linkage disequilibrium (red) to minimal linkage disequilibrium
(white). The numbers in the lower panels represent the pair-wise D’
values which are shown in two digits after the decimal point. Linkage
tests with LOD values ≥2 and D’ values >0.80 were considered as
presence of significant linkage. D’ values of 1.00 are not shown.
Additional file 3: The allele frequencies of tested APOA1/C3/A5
SNPs in breast cancer patients and healthy controls.
Additional file 4: The comparison of APOA1 rs670 A/A carriage with
other risk factors in predicting disease progression.Additional file 5: The Kaplan-Meier survival plots of APOA1 rs670
genotype carrying breast cancer patients. The recurrence-free (A and
C) and overall disease-specific survival (B and D) of APOA1 A/A (bold
line), G/A (thin line) and G/G (broke line) carrying breast cancer patients
were compared. Data from all recruited patients (n=223) are shown in A
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